Skip to content

The effects and security of Jiang Bai gastritis tablet on the treatment of chronic non-atrophic gastritis (Epigastric pain and cold coagulation syndrome of stagnation of Qi syndrome): randomized, double-blind, placebo-controlled, multi-center Phase ? clinical trial study

The effects and security of Jiang Bai gastritis tablet on the treatment of chronic non-atrophic gastritis (Epigastric pain and cold coagulation syndrome of stagnation of Qi syndrome): randomized, double-blind, placebo-controlled, multi-center Phase ? clinical trial study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004225
Enrollment
Unknown
Registered
2014-01-29
Start date
2014-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic non atrophic gastritis

Interventions

two group:High dose group
three group:middle dose group
four group:Low dose group

Sponsors

Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, West China School of Medicine, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Fulfilling the Western Medicine diagnosis of chronic non-atrophic gastritis; 2. Fulfilling the TCM diagnosis of Epigastric pain and cold coagulation syndrome of stagnation of Qi syndrome; 3. Aged between 18-65 years old; 4. Willing to participate and sign the inform consent.

Exclusion criteria

Exclusion criteria: (1) Combined stomach?duodenum ulcer, special type of gastritis, peptic ulcer, bleeding, gastric mucosa dysplasia or suspected malignant pathologically; (2) pathological examinations showed atrophy metaplasia lesions; (3) had received other TCM treatment to treat this disease in the last two weeks; (4) Distention symptoms cannot be excluded cardiovascular disease(Such as heart failure or cardiac insufficiency caused by flatulence), nervous system disease (Such as nervous vomiting), disorders of biliary tract (Such as gallstones); (5) Diarrhea and vomiting symptoms does not rule out acute gastroenteritis; (6) Combined cardiovascular, lung, liver, kidney and hematopoietic systems severe primary disease, or diseases which severely affect their survival, such as cancer or AIDS; (7) mental illness or legally disabled; (8) pregnancy or prepare pregnant women, Fertility planners; (9) allergies or allergic to the known ingredient of the test drug; (10) participated or are participating in clinical trials by other drugs within the past four weeks; (11) mental illness or alcohol / drug abuse history; Researchers who consider it’s not appropriate to participate in clinical trials. As the work environment changes frequently, causing loss to follow-up the situation.

Design outcomes

Primary

MeasureTime frame
The curative effect of TCM main symptoms;The VAS score data changes;TCM syndrome total score;Gastrointestinal disease PRO scale;

Countries

China

Contacts

Public ContactTang Wenfu

West China Hospital, Sichuan University

wftang900@126.com+86 18980602098

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026